{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:02:33Z","timestamp":1760644953586},"reference-count":19,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chem. Pharm. Bull.","CHEMICAL &amp; PHARMACEUTICAL BULLETIN"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1248\/cpb.53.172","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T06:04:09Z","timestamp":1107237849000},"page":"172-176","source":"Crossref","is-referenced-by-count":5,"title":["Quantitative Determination Method for Trace Amount of Penicillin Contaminants in Commercially Available Drug Product by HPLC Coupled with Tandem Mass Spectrometry"],"prefix":"10.1248","volume":"53","author":[{"given":"Wataru","family":"Takada","sequence":"first","affiliation":[{"name":"Analytical Research Laboratories, Fujisawa Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Adachi","sequence":"additional","affiliation":[{"name":"Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Kihara","sequence":"additional","affiliation":[{"name":"Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Analytical Research Laboratories, Fujisawa Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruyuki","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Analytical Research Laboratories, Fujisawa Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mifune","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Okayama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Saito","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Okayama University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.1999.00175.x"},{"key":"2","first-page":"31","volume":"49","author":"Ball P., Baquero F., Cars O., File","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"3","unstructured":"3) Consideration of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals, Guidance for Industry 78, U.S. Food and Drug Administrations, December 1999."},{"key":"4","unstructured":"4) Penicillins Summary Report, Council Regulation No. 2377\/90, Committee for Veterinary Medicinal Products, The European Agency for the Evaluation of Medicinal Products."},{"key":"5","unstructured":"5) Tolerance for Residues of New Animal Drugs in Food, Code of Federal Regulations, Title 21, Part 556, U.S. Food and Drug Administration."},{"key":"6","unstructured":"6) Current Good Manufacturing Practice for Finished Pharmaceuticals, Code of Federal Regulations, Title 21, Part 211, U.S. Food and Drug Administration."},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0231(19981230)12:24<2031::AID-RCM432>3.0.CO;2-8"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)00201-6"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)01266-3"},{"key":"10","unstructured":"10) Human Drug Cgmp Notes, U.S. Food and Drug Administration, Volume 8, Number 3, September 2000."},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00480-7"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(96)01004-7"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00353-3"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0231(19980915)12:17<1216::AID-RCM304>3.0.CO;2-O"},{"issue":"21","key":"15","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1021\/ac00093a019","volume":"66","year":"1994","journal-title":"Anal. Chem.","ISSN":"http:\/\/id.crossref.org\/issn\/0003-2700","issn-type":"print"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1002\/jms.425"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/jms.479"},{"key":"18","unstructured":"18) Text on Validation of Analytical Procedures, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q2A."},{"key":"19","unstructured":"19) Validation of Analytical Procedures: Methodology, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q2B."}],"container-title":["Chemical and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/cpb\/53\/2\/53_2_172\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T02:50:33Z","timestamp":1616035833000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/cpb\/53\/2\/53_2_172\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1248\/cpb.53.172","relation":{},"ISSN":["0009-2363","1347-5223"],"issn-type":[{"value":"0009-2363","type":"print"},{"value":"1347-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}